-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…
-
CICON17 Day 1 Recap: Neoantigens, Vaccines, and Overcoming Immunotherapy Resistance
Day 1 of CICON17 explored how to identify and target neoantigens with vaccines and other strategies to…
-
FDA Approves First-In-Class CAR T Cell Immunotherapy for Leukemia
Children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) can now receive the CD19-targeting CAR T…
-
Highlights of the 2nd Annual Rational Combinations 360° Conference
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential
-
Nivolumab Approved for Patients with Chemotherapy-Resistant, Metastatic, MSI-H Colorectal Cancer
Nivolumab becomes second checkpoint immunotherapy approved for colorectal cancer
-
Recapping Our 5th Annual Cancer Immunotherapy Month
The 5th Annual Cancer Immunotherapy Month generated more than 6,000,000 impressions and raised over $500,000.
-
Rational Combinations 360° Seeks Improved Immunotherapy Approaches for Patients
Top immunotherapy experts from both academia and industry will convene for the 2nd annual Rational Combinations 360°…
-
CRI’s CEO, Scientific Advisors Headline Cancer Immunotherapy Forum
The future of immunotherapy is in finding the right combinations
-
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
ASCO17’s presentations reveal that the field of immunotherapy is advancing along many fronts
